Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zosano Pharma Corp (ZSAN) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Zosano Pharma Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1587221.
Total stock buying since 2015: $1,834,855.
Total stock sales since 2015: $238,840.
Total stock option exercises since 2015: $184,714.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 0 | $0 | 36,279 | $7,878 | 0 | $0 |
| 2021 | 0 | $0 | 13,418 | $8,770 | 0 | $0 |
| 2019 | 100,000 | $350,000 | 0 | $0 | 0 | $0 |
| 2017 | 341,716 | $313,230 | 0 | $0 | 136,867 | $184,714 |
| 2016 | 275,454 | $363,598 | 211,468 | $222,192 | 0 | $0 |
| 2015 | 73,457 | $808,027 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-06 | 0 | $0 | 524 | $371 | 0 | $0 |
| 2022-03 | 0 | $0 | 35,755 | $7,507 | 0 | $0 |
| 2021-11 | 0 | $0 | 10,000 | $6,020 | 0 | $0 |
| 2021-06 | 0 | $0 | 3,418 | $2,750 | 0 | $0 |
| 2019-04 | 100,000 | $350,000 | 0 | $0 | 0 | $0 |
| 2017-12 | 105,000 | $64,485 | 0 | $0 | 0 | $0 |
| 2017-11 | 95,000 | $59,085 | 0 | $0 | 0 | $0 |
| 2017-05 | 141,716 | $189,660 | 0 | $0 | 9,478 | $0 |
| 2017-03 | 0 | $0 | 0 | $0 | 127,389 | $184,714 |
| 2016-09 | 0 | $0 | 34,942 | $26,006 | 0 | $0 |
| 2016-08 | 275,454 | $363,598 | 102,400 | $103,802 | 0 | $0 |
| 2016-07 | 0 | $0 | 74,126 | $92,384 | 0 | $0 |
| 2015-01 | 73,457 | $808,027 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-06-06 | Matthews Christine (Chief Financial Officer) | Sale | 82 | .71 | 58 |
| 2022-06-06 | Lo Steven (Chief Executive Officer) | Sale | 442 | .71 | 313 |
| 2022-03-31 | Matthews Christine (Chief Financial Officer) | Sale | 8,116 | .21 | 1,704 |
| 2022-03-31 | Lo Steven (Chief Executive Officer) | Sale | 23,633 | .21 | 4,962 |
| 2022-03-31 | Kellerman Donald J (VP, Clinical Dev & Med Affairs) | Sale | 4,006 | .21 | 841 |
| 2021-11-23 | Greathouse Kenneth | Sale | 10,000 | .60 | 6,020 |
| 2021-06-04 | Matthews Christine (Chief Financial Officer) | Sale | 1,709 | .81 | 1,375 |
| 2021-06-04 | Kellerman Donald J (VP, Clinical Dev & Med Affairs) | Sale | 1,709 | .81 | 1,375 |
| 2019-04-11 | Walker John Peter (President & CEO) | Buy | 100,000 | 3.50 | 350,000 |
| 2017-12-06 | Greathouse Kenneth (Director) | Buy | 55,000 | .61 | 33,385 |
| 2017-12-01 | Greathouse Kenneth (Director) | Buy | 50,000 | .62 | 31,100 |
| 2017-11-30 | Greathouse Kenneth (Director) | Buy | 45,000 | .62 | 27,945 |
| 2017-11-15 | Greathouse Kenneth (Director) | Buy | 15,000 | .58 | 8,670 |
| 2017-11-14 | Greathouse Kenneth (Director) | Buy | 35,000 | .64 | 22,470 |
| 2017-05-25 | Erbez Georgia (CFO and Chief Business Officer) | Buy | 68,000 | 1.32 | 89,760 |
| 2017-05-25 | Walker John Peter (Interim CEO) | Buy | 37,550 | 1.37 | 51,330 |
| 2017-05-24 | Walker John Peter (Interim CEO) | Buy | 36,166 | 1.34 | 48,570 |
| 2017-05-04 | Walker John Peter (Director) | Option Ex | 9,478 | .00 | 0 |
| 2017-03-20 | Alataris Konstantinos (President, CEO) | Option Ex | 127,389 | 1.45 | 184,714 |
| 2016-09-16 | Sandell Scott D (10% Owner) | Sale | 7,471 | .75 | 5,603 |
| 2016-09-16 | Barrett M James (10% Owner) | Sale | 7,471 | .75 | 5,603 |
| 2016-09-13 | Sandell Scott D (10% Owner) | Sale | 10,000 | .74 | 7,400 |
| 2016-09-13 | Barrett M James (10% Owner) | Sale | 10,000 | .74 | 7,400 |
| 2016-08-29 | Sandell Scott D (10% Owner) | Sale | 50,000 | 1.01 | 50,449 |
| 2016-08-29 | Barrett M James (10% Owner) | Sale | 50,000 | 1.01 | 50,449 |
| 2016-08-24 | Sandell Scott D (10% Owner) | Sale | 1,200 | 1.21 | 1,452 |
| 2016-08-24 | Barrett M James (10% Owner) | Sale | 1,200 | 1.21 | 1,452 |
| 2016-08-19 | Alataris Konstantinos (President, CEO) | Buy | 127,389 | 1.32 | 168,153 |
| 2016-08-19 | Lewis Hayley (VP, Reg Affairs & Quality) | Buy | 4,775 | 1.32 | 6,303 |
| 2016-08-19 | Erbez Georgia (Interim CFO) | Buy | 47,750 | 1.32 | 63,030 |
| 2016-08-19 | Xanthopoulos Kleanthis G (Director) | Buy | 15,920 | 1.32 | 21,014 |
| 2016-08-19 | Walker John Peter (Director) | Buy | 63,700 | 1.32 | 84,084 |
| 2016-08-19 | Kellerman Donald J (VP, Clinical Dev & Med Affairs) | Buy | 15,920 | 1.32 | 21,014 |
| 2016-07-21 | Sandell Scott D (10% Owner) | Sale | 8,989 | 1.33 | 11,955 |
| 2016-07-21 | Barrett M James (10% Owner) | Sale | 8,989 | 1.33 | 11,955 |
| 2016-07-20 | Sandell Scott D (10% Owner) | Sale | 14,158 | 1.24 | 17,555 |
| 2016-07-20 | Barrett M James (10% Owner) | Sale | 14,158 | 1.24 | 17,555 |
| 2016-07-19 | Sandell Scott D (10% Owner) | Sale | 534 | 1.17 | 624 |
| 2016-07-19 | Barrett M James (10% Owner) | Sale | 534 | 1.17 | 624 |
| 2016-07-13 | Sandell Scott D (10% Owner) | Sale | 13,382 | 1.20 | 16,058 |
| 2016-07-13 | Barrett M James (10% Owner) | Sale | 13,382 | 1.20 | 16,058 |
| 2015-01-30 | Biomed Realty L P (10% Owner) | Buy | 26,543 | 11.00 | 291,973 |
| 2015-01-30 | Sandell Scott D (10% Owner) | Buy | 23,457 | 11.00 | 258,027 |
| 2015-01-30 | Barrett M James (Director) | Buy | 23,457 | 11.00 | 258,027 |
Insider trading activities including stock purchases, stock sales, and option exercises of ZSAN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Zosano Pharma Corp (symbol ZSAN, CIK number 1587221) see the Securities and Exchange Commission (SEC) website.